133 related articles for article (PubMed ID: 16689763)
1. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis.
Diamandis M; Adam F; Kahr WH; Wang P; Chorneyko KA; Arsenault AL; Rivard GE; Hayward CP
J Thromb Haemost; 2006 May; 4(5):1086-94. PubMed ID: 16689763
[TBL] [Abstract][Full Text] [Related]
2. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.
Kahr WH; Zheng S; Sheth PM; Pai M; Cowie A; Bouchard M; Podor TJ; Rivard GE; Hayward CP
Blood; 2001 Jul; 98(2):257-65. PubMed ID: 11435291
[TBL] [Abstract][Full Text] [Related]
3. Quebec platelet disorder: features, pathogenesis and treatment.
Diamandis M; Veljkovic DK; Maurer-Spurej E; Rivard GE; Hayward CP
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):109-19. PubMed ID: 18277131
[TBL] [Abstract][Full Text] [Related]
4. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.
Sheth PM; Kahr WH; Haq MA; Veljkovic DK; Rivard GE; Hayward CP
Thromb Haemost; 2003 Aug; 90(2):293-8. PubMed ID: 12888877
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.
Veljkovic DK; Rivard GE; Diamandis M; Blavignac J; Cramer-Bordé EM; Hayward CP
Blood; 2009 Feb; 113(7):1535-42. PubMed ID: 19029443
[TBL] [Abstract][Full Text] [Related]
6. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.
Blavignac J; Bunimov N; Rivard GE; Hayward CP
Semin Thromb Hemost; 2011 Sep; 37(6):713-20. PubMed ID: 22102275
[TBL] [Abstract][Full Text] [Related]
7. Inherited disorders of the fibrinolytic pathway.
Jain S; Acharya SS
Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
[TBL] [Abstract][Full Text] [Related]
8. Thrombin generation abnormalities in Quebec platelet disorder.
Brunet JG; Sharma T; Tasneem S; Liang M; Wilson MD; Rivard GE; Hayward CPM
Int J Lab Hematol; 2020 Dec; 42(6):801-809. PubMed ID: 32761872
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.
Kunitada S; FitzGerald GA; Fitzgerald DJ
Blood; 1992 Mar; 79(6):1420-7. PubMed ID: 1547340
[TBL] [Abstract][Full Text] [Related]
10. Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets.
Baeten KM; Richard MC; Kanse SM; Mutch NJ; Degen JL; Booth NA
J Thromb Haemost; 2010 Jun; 8(6):1313-22. PubMed ID: 20180903
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
12. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.
Diamandis M; Paterson AD; Rommens JM; Veljkovic DK; Blavignac J; Bulman DE; Waye JS; Derome F; Rivard GE; Hayward CP
Blood; 2009 Feb; 113(7):1543-6. PubMed ID: 18988861
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
15. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
16. Bleeding risks associated with inheritance of the Quebec platelet disorder.
McKay H; Derome F; Haq MA; Whittaker S; Arnold E; Adam F; Heddle NM; Rivard GE; Hayward CP
Blood; 2004 Jul; 104(1):159-65. PubMed ID: 15026313
[TBL] [Abstract][Full Text] [Related]
17. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
Farrehi PM; Zhu Y; Fay WP
J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
[TBL] [Abstract][Full Text] [Related]
18. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
Sakata Y; Aoki N
J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
[TBL] [Abstract][Full Text] [Related]
19. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
20. Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder.
Liang M; Soomro A; Tasneem S; Abatti LE; Alizada A; Yuan X; Uusküla-Reimand L; Antounians L; Alvi SA; Paterson AD; Rivard GÉ; Scott IC; Mitchell JA; Hayward CPM; Wilson MD
Blood; 2020 Dec; 136(23):2679-2690. PubMed ID: 32663239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
